Neil Thomas, CBO since 2015
Dr Neil Thomas is a partner in Ventac Partners and joined Idogen in October 2014. He has worked in the biotechnology sector for over 20 years, with experience in company formation, fund-raising, IP portfolio management, business development, licensing and technology exploitation. Previously, he was director of Business Development & IP at Genetrix, Madrid and before that Director of IP & Technology at Roche spin-out BioXell in Milan. His experience also includes working in London-based European Patent Attorney firms, as well as assignments as a member of the board of Genetrix Life Sciences AB (Sweden), Biobide SL and Sensia SL. Neil Thomas holds a B.Sc. in Biological Sciences from the University of Birmingham and a Ph.D. in Biochemistry and Molecular Biology from the University of Durham. He was also Adjunct Professor of IP in the Life Sciences Industry at IE Business School in Madrid from 2010 to 2015.
Holdings: 31,429 shares. Neil Thomas also holds 14,57 percent of the shares in Ventac Holdings (Cyprus) Limited, holding 759,527 shares in Idogen.